Over the past few days, there has been much excitement around the globe about the potential antiviral role of molnupiravir against COVID-19. Interim analyses of the trial results (also known as the MOVe-OUT trial) about the efficacy and safety of molnupiravir in patients with COVID-19, released by Merck and Ridgeback on October 1, looked very promising. Such seemingly promising results even triggered a global sell-off of stocks of vaccines against COVID-19 (Forbes). Currently, Merck is planning to submit an application for Emergency Use Authorization (EUA) to the United States Food and Drug Administration (US FDA) as well as submit marketing applications to other regulatory bodies around the world. Between 1963 and early 2016, only about 90 drugs were formally approved to treat 9 human diseases caused by virus infection, including antivirals against HIV (Human Immunodeficiency Virus), HBV (Hepatitis B Virus), HCV (Hepatitis C Virus), HSV (Herpes Simplex Viruses), HCMV (Human Cytomegalovirus), HPV (Human Papillomavirus), RSV (Respiratory Syncytial Virus), VZV....